Uveal melanoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m Bot: Removing from Primary care |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}{{AE}}{{Fs}}, {{Simrat}} | {{CMG}}{{AE}}{{Fs}}, {{Simrat}} | ||
==Overview== | ==Overview== | ||
Pharmacologic medical therapy is recommended among [[Patient|patients]] with [[Metastasis|metastatic]] [[disease]] and include [[chemotherapy]], [[immunotherapy]], and [[targeted therapy]]. | |||
==Medical Therapy== | ==Medical Therapy== | ||
Pharmacologic medical therapy is recommended among patients with metastatic disease: | Pharmacologic medical [[therapy]] is recommended among [[Patient|patients]] with [[Metastasis|metastatic]] disease:<ref name="pmid29497459">{{cite journal |vauthors=Yang J, Manson DK, Marr BP, Carvajal RD |title=Treatment of uveal melanoma: where are we now? |journal=Ther Adv Med Oncol |volume=10 |issue= |pages=1758834018757175 |date=2018 |pmid=29497459 |pmc=5824910 |doi=10.1177/1758834018757175 |url=}}</ref><ref name="pmid26601868">{{cite journal |vauthors=Shoushtari AN, Carvajal RD |title=Treatment of Uveal Melanoma |journal=Cancer Treat. Res. |volume=167 |issue= |pages=281–93 |date=2016 |pmid=26601868 |doi=10.1007/978-3-319-22539-5_12 |url=}}</ref> | ||
* Chemotherapy | *'''[[Chemotherapy]]''' | ||
** Dacarbazine | **[[Dacarbazine]] | ||
** Temozolomide | **[[Temozolomide]] | ||
** Cisplatin | **[[Cisplatin]] | ||
** Treosulfan | **[[Treosulfan]] | ||
** Fotemustine | **[[Fotemustine]] | ||
* Immunotherapy | *'''[[Immunotherapy]]''' | ||
** Checkpoint blockade | ** Checkpoint blockade | ||
*** Pembrolizumab | ***[[Pembrolizumab]] | ||
*** Ipilimumab + nivolumab | ***[[Ipilimumab]] + [[nivolumab]] | ||
*** Ipilimumab + nivolumab | ***[[Ipilimumab]] + [[nivolumab]] | ||
*** Ipilimumab + radioembolization | ***[[Ipilimumab]] + radioembolization | ||
*** Ipilimumab + nivolumab +radioembolization | ***[[Ipilimumab]] + [[nivolumab]] +radioembolization | ||
** TILs (tumor-infiltrating lymphocytes) | ** TILs (tumor-infiltrating lymphocytes) | ||
** T cell redirection | **[[T cell]] redirection | ||
** | **[[Antibody]]–[[drug]] conjugate | ||
*** Glembatumumab vedotin | *** Glembatumumab vedotin | ||
* Targeted therapy | *[[Targeted therapy|'''Targeted therapy''']] | ||
** PKC (protein kinase | **[[Protein kinase C|PKC]] ([[protein kinase C]])/ MEK | ||
*** AEB071 + BYL719 | *** AEB071 + BYL719 | ||
*** Intermittent selumetinib | *** Intermittent selumetinib | ||
*** Selumetinib +/– paclitaxel | *** Selumetinib +/– [[paclitaxel]] | ||
*** Binimetinib + AEB071 | ***[[Binimetinib]] + AEB071 | ||
** | ** Multi-kinase inhibition | ||
*** Sorafenib (STREAM) | ***[[Sorafenib]] (STREAM) | ||
*** Cabozantinib versus temozolomide/ dacarbazine | ***[[Cabozantinib]] versus [[temozolomide]]/ [[dacarbazine]] | ||
** Epigenetic therapy | ** Epigenetic therapy | ||
*** HDAC (histone deacetylase) inhibition | ***[[Histone deacetylase 2|HDAC]] ([[histone deacetylase]]) inhibition | ||
**** Vorinostat | ****[[Vorinostat]] | ||
**** Pembrolizumab + entinostat (PEMDAC) | ****[[Pembrolizumab]] + entinostat (PEMDAC) | ||
*** BET (bromodomain and extra-terminal motif) inhibition | *** BET (bromodomain and extra-terminal motif) inhibition | ||
** Liver-directed therapy | ** Liver-directed therapy | ||
*** IHP (isolated hepatic perfusion) | *** IHP (isolated [[hepatic]] perfusion) | ||
*** PHP ( <br /> | *** PHP (percutaneous isolated hepatic perfusion) with melphalan<br /> | ||
== References == | == References == | ||
| Line 48: | Line 49: | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Surgery]] | [[Category:Surgery]] | ||
Latest revision as of 00:37, 30 July 2020
|
Uveal melanoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Uveal melanoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Uveal melanoma medical therapy |
|
Risk calculators and risk factors for Uveal melanoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D., Simrat Sarai, M.D. [2]
Overview
Pharmacologic medical therapy is recommended among patients with metastatic disease and include chemotherapy, immunotherapy, and targeted therapy.
Medical Therapy
Pharmacologic medical therapy is recommended among patients with metastatic disease:[1][2]
- Chemotherapy
- Immunotherapy
- Checkpoint blockade
- Pembrolizumab
- Ipilimumab + nivolumab
- Ipilimumab + nivolumab
- Ipilimumab + radioembolization
- Ipilimumab + nivolumab +radioembolization
- TILs (tumor-infiltrating lymphocytes)
- T cell redirection
- Antibody–drug conjugate
- Glembatumumab vedotin
- Checkpoint blockade
- Targeted therapy
- PKC (protein kinase C)/ MEK
- AEB071 + BYL719
- Intermittent selumetinib
- Selumetinib +/– paclitaxel
- Binimetinib + AEB071
- Multi-kinase inhibition
- Sorafenib (STREAM)
- Cabozantinib versus temozolomide/ dacarbazine
- Epigenetic therapy
- HDAC (histone deacetylase) inhibition
- Vorinostat
- Pembrolizumab + entinostat (PEMDAC)
- BET (bromodomain and extra-terminal motif) inhibition
- HDAC (histone deacetylase) inhibition
- Liver-directed therapy
- IHP (isolated hepatic perfusion)
- PHP (percutaneous isolated hepatic perfusion) with melphalan
- PKC (protein kinase C)/ MEK
References
- ↑ Yang J, Manson DK, Marr BP, Carvajal RD (2018). "Treatment of uveal melanoma: where are we now?". Ther Adv Med Oncol. 10: 1758834018757175. doi:10.1177/1758834018757175. PMC 5824910. PMID 29497459.
- ↑ Shoushtari AN, Carvajal RD (2016). "Treatment of Uveal Melanoma". Cancer Treat. Res. 167: 281–93. doi:10.1007/978-3-319-22539-5_12. PMID 26601868.